• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Rises 1%; Verastem Shares Slide

    5/24/24 2:47:50 PM ET
    $AKAN
    $DECK
    $GNLX
    $MRUS
    Medicinal Chemicals and Botanical Products
    Health Care
    Shoe Manufacturing
    Consumer Discretionary
    Get the next $AKAN alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Friday.

    The Dow traded up 0.12% to 39,112.74 while the NASDAQ rose 1.08% to 16,917.09. The S&P 500 also rose, gaining, 0.70% to 5,304.78.

    Check This Out: Top 3 Health Care Stocks That May Crash In May

    Leading and Lagging Sectors

    Communication services shares jumped by 1.3% on Friday.

    In trading on Friday, health care shares fell by 0.1%.

    Top Headline

    The total number of active U.S. oil rigs came in unchanged at 497 rigs this week, Baker Hughes Inc reported.

    Equities Trading UP
                           

    • Akanda Corp. (NASDAQ:AKAN) shares shot up 34% to $3.2001. The international medical cannabis company implemented a 1-for-40 reverse stock split on its ordinary shares effective May 23, 2024, according to a recent exchange filing.
    • Shares of Merus N.V. (NASDAQ:MRUS) got a boost, surging 34% to $58.86 after the company announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 ASCO Annual Meeting website.
    • Deckers Outdoor Corporation (NYSE:DECK) shares were also up, gaining 13% to $1,026.72 after the company reported better-than-expected quarterly financial results.

    Equities Trading DOWN

    • Verastem, Inc. (NASDAQ:VSTM) shares dropped 65% to $4.2550. The company announced that it initiated the rolling submission of a NDA to the FDA for accelerated approval of the combination of avutometinib and defactinib for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer.
    • Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) were down 21% to $7.58. TriSalus Life Sciences announced commencement of exchange offer and consent solicitation relating to warrants.
    • Genelux Corporation (NASDAQ:GNLX) was down, falling 41% to $2.72 after the company reported pricing of approximately $27.5 million underwritten offering of common stock and accompanying warrants.

    Also Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Financial Stocks Delivering High-Dividend Yields

    Commodities

    In commodity news, oil traded up 1.1% to $77.74 while gold traded down 0.1% at $2,334.20.

    Silver traded up 0.1% to $30.455 on Friday, while copper fell 0.7% to $4.76.

    Euro zone

    European shares were mostly lower today. The eurozone's STOXX 600 fell 0.19%, Germany's DAX gained 0.01% and France's CAC 40 slipped 0.09%. Spain's IBEX 35 Index fell 0.58%, while London's FTSE 100 declined 0.26%.

    Producer prices in Spain declined by 6.6% year-over-year in April compared to an 8.2% fall in March. The manufacturing climate indicator in France declined to a reading of 99 in May. German economy grew by 0.2% quarter-over-quarter in the three months to March versus a 0.5% contraction in the prior period. Retail sales in the UK fell 2.3% month-over-month for April versus a revised 0.2% decline a month ago.

    Asia Pacific Markets

    Asian markets closed lower on Friday, with Japan's Nikkei falling 1.17%, China's Composite Index declining 0.88%, Hong Kong's Hang Seng Index falling 1.38% and India's S&P BSE Sensex falling 0.1%.

    The annual inflation rate in Japan eased to 2.5% in April versus 2.7%, while core consumer price index in Japan increased 2.2% year-over-year in April versus a 2.6% rise in the prior month.

    Economics

    • U.S. durable goods orders increased by 0.7% month-over-month in April compared to a revised 0.8% gain in March. However, markets were expecting for a 0.8% decrease.
    • The total number of active U.S. oil rigs unchanged at 497 rigs this week, Baker Hughes Inc reported.

    Now Read This: Apple To Rally Over 47%? Here Are 10 Top Analyst Forecasts For Friday

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $DECK
    $GNLX
    $MRUS

    CompanyDatePrice TargetRatingAnalyst
    Verastem Inc.
    $VSTM
    2/4/2026$18.00Buy
    H.C. Wainwright
    Deckers Outdoor Corporation
    $DECK
    1/30/2026$105.00 → $120.00Market Perform
    Telsey Advisory Group
    Deckers Outdoor Corporation
    $DECK
    1/14/2026$102.00Hold
    Jefferies
    Deckers Outdoor Corporation
    $DECK
    1/7/2026$85.00Neutral → Underweight
    Piper Sandler
    Deckers Outdoor Corporation
    $DECK
    1/7/2026$125.00Outperform → Neutral
    Robert W. Baird
    Deckers Outdoor Corporation
    $DECK
    12/10/2025Neutral
    Guggenheim
    Deckers Outdoor Corporation
    $DECK
    11/18/2025$117.00Hold → Buy
    Stifel
    Deckers Outdoor Corporation
    $DECK
    10/24/2025$120.00 → $105.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $AKAN
    $DECK
    $GNLX
    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Stansky Michael P

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/11/26 6:51:12 PM ET
    $TLSI
    Medical Specialities
    Health Care

    New insider Stansky Michael P claimed ownership of 625,732 shares (SEC Form 3)

    3 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/11/26 6:50:03 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Chief Financial Officer Fasching Steven J. covered exercise/tax liability with 1,079 shares, decreasing direct ownership by 0.64% to 166,662 units (SEC Form 4)

    4 - DECKERS OUTDOOR CORP (0000910521) (Issuer)

    2/10/26 12:16:56 PM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    $AKAN
    $DECK
    $GNLX
    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 6, 2024 - FDA Roundup: December 6, 2024

    For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

    12/6/24 3:09:02 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $DECK
    $GNLX
    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Verastem with a new price target

    H.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00

    2/4/26 8:31:21 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telsey Advisory Group reiterated coverage on Deckers Outdoor with a new price target

    Telsey Advisory Group reiterated coverage of Deckers Outdoor with a rating of Market Perform and set a new price target of $120.00 from $105.00 previously

    1/30/26 6:49:41 AM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    Jefferies resumed coverage on Deckers Outdoor with a new price target

    Jefferies resumed coverage of Deckers Outdoor with a rating of Hold and set a new price target of $102.00

    1/14/26 8:40:20 AM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    $AKAN
    $DECK
    $GNLX
    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UGG Redefines Men's Fashion in Latest Spring 2026 Campaign Fronted by Global Icons Central Cee & Su Yiming

    Brand Introduces New Styles That Tell Story of Reinvention & Versatility Through Culture Icons Southern California-based global lifestyle brand UGG® (a division of Deckers Brands (NYSE: DECK)) releases the next offering of clogs and mules for Spring 2026, this time featuring new silhouettes and styles derived from the fan-favorite UGG® Tasman. To showcase the release of these soon-to-be consumer favorites, UGG® tapped global rap sensation Central Cee and Olympic snowboarding champion Su Yiming to be the faces of the newest campaign to celebrate elevated versatility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260213443896/e

    2/13/26 9:00:00 AM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun "JJ" Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board expressed their sincere appreciation for Dr. Desai's service and contributions during his tenure. Concurrently, TriSalus announced that Michael P. Stansky has been appointed to the Company's Board of Directors, effective February 4, 2026

    2/9/26 9:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $AKAN
    $DECK
    $GNLX
    $MRUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/29/25 5:16:48 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/22/25 5:15:45 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $DECK
    $GNLX
    $MRUS
    SEC Filings

    View All

    TriSalus Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    2/9/26 8:59:49 AM ET
    $TLSI
    Medical Specialities
    Health Care

    Verastem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Verastem, Inc. (0001526119) (Filer)

    2/4/26 7:30:33 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Deckers Outdoor Corporation

    10-Q - DECKERS OUTDOOR CORP (0000910521) (Filer)

    2/3/26 11:42:49 AM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    $AKAN
    $DECK
    $GNLX
    $MRUS
    Financials

    Live finance-specific insights

    View All

    Deckers Brands Reports Third Quarter Fiscal Year 2026 Financial Results

    Third Quarter FY 2026 Revenue Increased 7% to a Record $1.96 Billion Third Quarter FY 2026 Diluted EPS Increased 11% to a Record $3.33 FY 2026 HOKA Revenue Guidance Raised to Mid-teens Percent Increase FY 2026 UGG Revenue Guidance Raised to Mid-single-digits Percent Increase FY 2026 Diluted EPS Guidance Raised to Range of $6.80-$6.85 FY 2026 Share Repurchase Expected to Exceed $1.0 Billion Deckers Brands (NYSE:DECK), a global leader in designing, marketing, and distributing innovative footwear, apparel, and accessories, today announced financial results for the third fiscal quarter ended December 31, 2025. The Company also provided an update to its financial outlook for t

    1/29/26 4:05:00 PM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    Deckers Brands Announces Conference Call to Review Third Quarter Fiscal 2026 Earnings Results

    Deckers Brands (NYSE:DECK), a global leader in designing, marketing and distributing innovative footwear, apparel and accessories, today announced that the Company's conference call to review third quarter fiscal 2026 results will be on Thursday, January 29, 2026 at approximately 4:30 pm Eastern Time. The broadcast will be hosted at ir.deckers.com. The broadcast will be available for at least 30 days following the conference call. About Deckers Brands Deckers Brands is a global leader in designing, marketing, and distributing innovative footwear, apparel, and accessories developed for both everyday casual lifestyle use and high-performance activities. The Company's portfolio of brands i

    1/20/26 9:05:00 AM ET
    $DECK
    Shoe Manufacturing
    Consumer Discretionary

    TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

    Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year Full-year 2025 revenue growth of approximately 53% exceeded 2025 guidance Set initial 2026 revenue guidance of approximately $60-$62 million TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and full-year

    1/12/26 7:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $AKAN
    $DECK
    $GNLX
    $MRUS
    Leadership Updates

    Live Leadership Updates

    View All

    TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun "JJ" Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board expressed their sincere appreciation for Dr. Desai's service and contributions during his tenure. Concurrently, TriSalus announced that Michael P. Stansky has been appointed to the Company's Board of Directors, effective February 4, 2026

    2/9/26 9:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

    1/2/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $DECK
    $GNLX
    $MRUS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $DECK
    $GNLX
    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by TriSalus Life Sciences Inc.

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    12/4/24 4:00:06 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 6:25:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:38:53 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care